What are the characteristics of ABL Diagnostics stock?

ABL Diagnostics is a company operating in the Diagnostic / labos d'analyse sector. The stock is listed on Euronext Paris under ISIN FR001400AHX6.

What is the recent price evolution of ABL Diagnostics stock?

Since last close: -0.9 %. Over one week: -1.79 %. Over one year: -50.89 %.

ABL Diagnostics Doubles Its Dividend to €0.11 per Share for 2025

ABL Diagnostics approved a dividend of €0.11 per share for the fiscal year 2025 on June 30, up from €0.05 paid for 2024, reflecting improved results and the financial strength of the group.

Published on Jul 03, 2026 at 09:44

ABL Diagnostics

2.20 € -0.90 %

Add us as a preferred source on Google

Ex-dividend and Payment Dates Set for July

The dividend will be detached on July 3, 2026, and paid on July 7, 2026. This represents a 120% increase in the dividend compared to the previous fiscal year, amounting to a gross €0.11 per share.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

🏢 Other stocks — Santé

🗞️ Genfit stock slides 4.5%, among the largest declines on the SBF 120 🗞️ Among the worst performers in the SBF 120, Valneva shares fall 4.5% following Ixchiq setback 🗞️ Emeis share breaks through its 10.02 € support level, RSI falls to 24 🗞️ GenSight Biologics: Cash Position of €0.7M at End of September, €16M Needed for Recover

Context

Period

Period: S1 2026

Key reported figures

Revenue: 5,4 millions d'euros
Quarterly revenue: 5,4 millions d'euros
Revenue growth: 90,1 %
EBITDA: 1,3 millions d'euros
EBITDA margin: 24,3 %
Net income: 1,3 millions d'euros
1 millions d'euros

Guidance from the release

The achievement of this objective remains dependent on: the timing of orders and deliveries; the ramp-up of the UltraGene range; the development of HIV activities; the contribution of Vela Diagnostics and CDL Pharma; supply conditions; regulatory deadlines

Risks mentioned

Timing of orders and deliveries remains uncertain and critical to achieving 2026 targets
Ramp-up execution of UltraGene range and HIV activities could face delays or operational challenges
Integration of Texcell France operations needs to successfully combine cultures and operations while maintaining financial discipline

Opportunities identified

Ramp-up of the UltraGene range (formerly Fast Track Diagnostics) with €1.582 million target for 2026
Expansion of HIV activities with €3.906 million annual target
Integration of Texcell France assets acquired in July 2026, adding 29 new employees and new virology and biosafety testing services

Outlook / guidance

Expected revenue: 12,3 millions d'euros
Management commentary: On June 1, 2026, ABL Diagnostics published a roadmap targeting annual revenue of €12.265 million in 2026, compared to €6.950 million in 2025, i.e. a targeted annual growth of 76.5%.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Ex-dividend and Payment Dates Set for July

Context

Also read